ACADIA Pharmaceuticals (ACAD) capped FY 2025 with Q4 revenue of US$284 million and basic EPS of US$1.62, while trailing 12 month revenue reached about US$1.1 billion and basic EPS came in at US$2.32 as the company reported net profit margins of 36.5% over the last year, up from 23.6% the prior year. Over the past year, ACADIA has seen earnings grow 72.7% with a 5 year average earnings growth rate of 66.5% per year, and analysts currently expect earnings to grow about 8.2% per year alongside roughly 10.4% annual revenue growth. This sets up a results season where investors are weighing margin expansion against more moderate forward growth expectations.

See our full analysis for ACADIA Pharmaceuticals.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the widely held narratives around ACADIA, and where the latest figures might challenge those views.

Margins Step Up To 36.5%

• Over the last 12 months, ACADIA converted US$1.1b of revenue into US$391 million of net income, which works out to a 36.5% net margin compared with 23.6% the prior year in the dataset.
• Bulls highlight that this margin profile fits with their view of meaningful expansion, and the reported 72.7% trailing earnings growth gives some backing to that idea, yet:
  • Consensus in the data still only looks for around 8.2% annual earnings growth and 10.4% annual revenue growth, which is far lower than the very large uplift implied by bullish scenarios.
  • Forecast margins in the balanced view are essentially flat at around 21.6% in 3 years, which is well below the current 36.5% level and a clear check on the most optimistic margin assumptions.

Over the past year ACADIA has put up strong margins, and bulls argue that this could be the early stages of the kind of earnings power their thesis leans on, so it is worth seeing how that case is built out in the full narrative: 🐂 ACADIA Pharmaceuticals Bull Case

Earnings Growth Slows From 72.7% To 8.2% Forecast

• The data shows trailing 12 month earnings growth of 72.7%, but forward expectations step down to about 8.2% a year for earnings and 10.4% a year for revenue, which is also below the cited 15.7% annual earnings growth forecast for the broader US market.
• Bears focus on that slowdown, arguing growth may be too limited to justify aggressive views on the stock, and the figures here speak directly to that concern:
  • The bearish narrative in the inputs assumes earnings could drop to US$57.1 million by around 2028, compared with the US$391 million trailing net income in the dataset, which would be a very large pullback versus the historical growth rate.
  • Even the more balanced consensus case only looks for US$306 million of earnings by 2028, which sits well below the bullish US$625.1 million scenario and underlines how sensitive the story is to where growth actually settles.

Skeptics point to how quickly the growth outlook in the data cools from 72.7% to single digits, so if you want to see how that feeds into a more cautious storyline on ACADIA, the full bear case lays it out in detail: 🐻 ACADIA Pharmaceuticals Bear Case

Low 10.7x P/E Versus DCF Fair Value Of US$148.13

• On the valuation side, the dataset shows ACADIA trading on a 10.7x P/E at a US$24.64 share price, compared with an industry average near 23x and a DCF fair value of US$148.13 in the model, which frames a large gap between price and the modelled cash flow value.
• Consensus narrative in the inputs leans on steady revenue growth and a broadening pipeline to support its view, and the numbers give a mixed read against that:
  • Analysts in the balanced case look for earnings of US$306 million by about 2028 and a P/E of 21x at a price target of US$31.55, which is higher than the current 10.7x multiple but still well below the DCF fair value level.
  • At the same time, forecast earnings growth in the data, at around 8.2% a year, sits below the broader US market forecast of 15.7% a year, so the comparatively low P/E and large DCF gap come with growth expectations that are more modest than the market overall.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for ACADIA Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of strong margins, cooler growth forecasts and valuation gaps leaves you unsure, act while the data is fresh and shape your own view. A good place to start is by checking the specific rewards our analysis has highlighted for the company, including 4 key rewards.

See What Else Is Out There

ACADIA pairs strong recent margins with forecasts that point to much slower earnings and revenue growth, plus a valuation story that relies heavily on model assumptions.

If that mix of cooler growth expectations and model dependent valuation feels uneasy, you can quickly compare it with 54 high quality undervalued stocks to screen for companies where current pricing and fundamentals look more tightly aligned, so start checking those alternatives now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.